Neonatal Clinical Trial
Official title:
Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants
Study Hypothesis: Preterm infants administered weekly Darbe during the neonatal period will have improved neurocognitive outcome at 22-26 months compared to placebo
Advances in neonatal care have led to significant improvements in the survival of the nearly 60,000 very low birth weight (VLBW) infants born each year in the U.S. Improving neurodevelopmental outcomes for these preterm infants continues to be a major goal for neonatal care providers. A subset of these infants sustain a grade 3 or 4 intraventricular hemorrhage (IVH) resulting in an increase in the incidence of developmental delay. Moreover, almost one third of preterm infants with normal head ultrasounds also develop cognitive delay. Although a variety of neuroprotective treatment strategies have been evaluated, no specific treatment has been identified to reduce or prevent brain injury in these most vulnerable preterm infants. A potential neuroprotective therapy involves administering erythropoiesis stimulating agents (ESAs) such as erythropoietin (Epo) and Darbepoetin (Darbe, a longer acting ESA). In addition to stimulating erythropoiesis, ESAs have been shown to be protective in the developing brain in animal models, making it possibly beneficial for very premature infants who are at risk for intraventricular hemorrhage, hypoxic-ischemic injury, and developmental delay. The neuroprotective mechanisms of ESAs include increased neurogenesis, decreased neuronal susceptibility to glutamate toxicity, decreased neuronal apoptosis, decreased inflammation, decreased nitric oxide-mediated injury, increased antioxidant response, decreased axonal degeneration, and increased protective effects on glia. This is a randomized, masked, placebo controlled clinical study in which enrolled infants will receive weekly Darbe or placebo (sham) dosing. Extended follow-up: Subjects will be seen for follow-up at 4-5 years (i.e., 4 years - 4 years 11 months) corrected age and 6-7 years (i.e., 6 years - 6 years 11 months) corrected age to characterize the functional, behavioral and neurological outcomes of the extremely low birth weight (ELBW) population at school age based on treatment with darbepoetin versus placebo in the neonatal period. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04523441 -
Early Support and Physiotherapy for Children and Their Motor Skills
|
||
| Completed |
NCT05828420 -
The Effect of Music, White Noise and Heart Sound on Neonatal Pain
|
N/A | |
| Completed |
NCT03272594 -
The Influence of Breastfeeding on Cortical Activity During Procedures
|
Phase 3 | |
| Recruiting |
NCT06344741 -
Consequences of Admission to the Delivery Room in the Early and Late Phases
|
||
| Completed |
NCT05036915 -
The Effect of Routine and Random Pacifier Use Methods in Preterm Infants
|
N/A | |
| Recruiting |
NCT05223790 -
Assessment of the NIPE in Very Premature Infant Ventilated and Sedated in Neonatal Reanimation.
|
||
| Completed |
NCT05221463 -
The Effect of Video-assisted Breastfeeding Education Given to Mothers of Hospitalized Newborns on Breastfeeding
|
N/A | |
| Completed |
NCT04354467 -
Assessment of Urinary Neutrophil Gelatinase-Associated Lipocalin to Predict AKI in the NICU
|
||
| Active, not recruiting |
NCT02545712 -
Safe Excipient Exposure in Neonates and Small ChildreN
|
N/A | |
| Not yet recruiting |
NCT05451875 -
Comparison of Continuous Non-invasive All Vital Signs Monitoring Devices With Invasive Gold Standard for Children
|
||
| Active, not recruiting |
NCT04295564 -
Extending CPAP Therapy in Stable Preterm Infants to Increase Lung Growth and Function
|
Phase 2/Phase 3 | |
| Withdrawn |
NCT02764528 -
Intervention Study to Improve Maternal Handwashing
|
N/A | |
| Completed |
NCT02379936 -
Evaluation of Lactate Dehydrogenase as Decision Support for Admissions to Neonatal Ward
|
N/A | |
| Recruiting |
NCT04545866 -
The Budesonide in Babies (BiB) Trial
|
Phase 3 |